MaxCyte ( (MXCT) ) just unveiled an update.
MaxCyte announced that John Johnston, a Non-Executive Director, exercised options for 3,000 shares of common stock, which were subsequently sold. This transaction, conducted under a pre-established trading plan, resulted in Johnston’s holdings adjusting to 120,583 shares and 171,918 options. This move reflects underlying strategic financial management within MaxCyte, potentially impacting its market positioning and stakeholder interests.
More about MaxCyte
MaxCyte, Inc. is a leading company in the cell engineering industry, specializing in platform technologies that facilitate the advancement of next-generation cell therapeutics. The company focuses on the rapidly expanding cell therapy market, offering the ExPERT™ platform based on Flow Electroporation® technology, which supports the continuum from discovery to commercialization of cell-based medicines.
YTD Price Performance: 16.36%
Average Trading Volume: 64,559
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £389.9M
For a thorough assessment of MXCT stock, go to TipRanks’ Stock Analysis page.